Post by Galderma

We are pleased to report a strong start to 2026 with net sales of 1.473 billion USD in the first quarter, up 25.5% year-on-year at constant currency. Our widespread growth was aligned with strong performance across geographies and product categories. Sales in Injectable Aesthetics grew by 13.1%, while Dermatological Skincare performed ahead of expectations at 17.0%. In Therapeutic Dermatology, the launch trajectory of our novel biologic for atopic dermatitis and prurigo nodularis supported outstanding growth of +71.3%. We demonstrated our scientific leadership with new data across product categories presented at global congresses, including positive phase II data on our novel biologic and pioneering research on menopause-related skin changes. Thanks to the solid results across our portfolio, we have confirmed our 2026 full-year guidance on net sales to +17-20% year-on-year growth at constant currency. Our outstanding Q1 performance reflects our increasing confidence to navigate a volatile environment as we advance further toward our ambition to become the world’s undisputed dermatology powerhouse. Hear our CEO, Flemming Ornskov, MD, MPH discuss our Q1 2026 performance in the video below, and read more here: https://lnkd.in/eX9TrXfy #AdvancingDermatology #Q1results #GALD

Video Content